Navigation Links
deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
Date:10/12/2011

REYKJAVIK, Iceland, October 12, 2011 /PRNewswire/ --

deCODE genetics today announced that it has entered into a research collaboration with Pfizer Inc., the objective of which is to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis by utilizing deCODE's expertise in gene discovery.

deCODE's discovery capabilities combine its extensive population and genetic resources, including DNA samples and medical data, complete genealogical information, next generation sequencing technology, and deCODE's proprietary bioinformatics and statistical capabilities. Over the next 18 months, deCODE and Pfizer will work together to analyse the genomes of patients to search for sequence variants that would be useful for understanding drug targets and discovering novel drug targets, that may ultimately lead to tools for patient stratification and companion diagnostics.

"This agreement is a part of deCODE's ongoing strategy to unleash the value of human genetics," said Kari Stefansson, founder and CEO of deCODE, "our research platform allows us to understand the genetic basis of disease and modifiers of clinical phenotypes in actual patient populations; by doing so, we can rapidly move from targets to patient stratification and from there to companion diagnostics."

The research collaboration will utilize the expertise and capabilities of both deCODE and Pfizer: deCODE's comprehensive population genetics resources and analytical expertise and Pfizer's dedication to the application of genomic analysis to the discovery and development of drugs.

About deCODE

Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.

In order to most rapidly realize the value of genetics for human health, deCODE is currently partnering with life sciences companies to accelerate their target discovery, validation, and prioritization efforts, yielding improved patient stratification for clinical trials and essential companion diagnostics. In addition, through its CLIA- and CAP-certified laboratory, deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases.  deCODE also licenses its tests, intellectual property, and analytical tools to partner organizations.  deCODE's corporate information can be found at http://www.decode.com with information about our genetic testing services at http://www.decodehealth.com and http://www.decodeme.com

Contact:
Gisli Arnason
+354-570-1825
gisli.arnason@decode.is


'/>"/>

SOURCE deCODE genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
2. deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers
3. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
4. The New deCODE Map of the Human Genome
5. deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma
6. ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test
7. deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases
8. deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk
9. deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal
10. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
11. Amaizing: Corn genome decoded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):